A Unique Interaction of IVS-I-1 (G > A) (HBA2: c.95+1G > A) with Hb Adana (HBA2: c.179G > A) Presenting as Transfusion-Dependent -Thalassemia
HEMOGLOBIN
Authors: Alauddin, Hafiza; Kamarudin, Khairina; Loong, Tang Yee; Azma, Raja Zahratul; Ithnin, Azlin; Jalil, Norunaluwar; Razak, Noor-Farisah; Koh-Xuan-Rong, Danny; Ismail, Endom; C-Khai, Loh; Latiff, Zarina Abdul; Alias, Hamidah; Othman, Ainoon
Abstract
Nondeletional -globin mutations are known to cause more serious clinical effects than deletional ones. A rare IVS-I-1 (G>A) (HBA2: c.95+1G>A) donor splice site mutation interferes with normal splicing of pre mRNA and results in activation of a cryptic splice site as well as a frameshift mutation. Hb Adana [HBA2: c.179G>A (or HBA1)] is a highly unstable variant hemoglobin (Hb) resulting from a mutation at codon 59 on the HBA2 or HBA1 gene, recognized to cause severe -thalassemia (-thal) syndromes. We report a unique case of compound heterozygosity for these two mutations in a 9-year-old boy who presented with a Hb level of 5.3g/dL and hepatomegaly at the age of 15months. He required regular blood transfusions in view of a Hb level of <7.0g/dL and failure to thrive. He had thalassemic red cell indices and peripheral blood film. The Hb electrophoresis only showed a raised Hb F level (3.3%) and a pre run peak but the Hb H inclusion test was negative. His father had thalassemic red cell indices but a normal Hb level. His mother had almost normal Hb levels and red cell indices. Hb Adana involving the HBA2 gene was detected by mutiplex amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) in the proband and his father. DNA sequencing of the HBA2 gene confirmed the IVS-I-1 mutation in the proband and his mother. This case highlighted the unique interaction of the IVS-I-1 mutation with Hb Adana in a young Malay boy presenting with transfusion-dependent -thal.
Severe Drug-Induced Hemolysis in a Patient with Compound Heterozygosity for Hb Peterborough (HBB: c.334G > T) and Hb Lepore-Boston-Washington (NG_000007.3: g.63632_71046del)
HEMOGLOBIN
Authors: Agbuduwe, Charles; Rugless, Michelle; Asba, Nigel; Proven, Melanie; Sivakumaran, Muttuswamy
Abstract
Unstable hemoglobins (Hbs) are often overlooked in the differential diagnoses of drug-induced hemolysis. Hb Peterborough [beta 111(G13)Val -> Phe; HBB: c.334G>T] is a rare unstable Hb variant, predominantly found in individuals of Italian descent, due to a structural defect involving a single amino acid substitution (phenylalanine for valine at position 111 of the beta-globin chain). Unstable Hb variants are often inherited in the heterozygous state with Hb A (alpha 2 beta 2) and rarely in compound heterozygosity with other Hb variants. The presence of another variant Hb often alters the phenotype, occasionally resulting in more severe disease. Using a combination of molecular techniques; multiplex ligation-dependent probe amplification (MLPA) and Sanger sequencing, we identified a compound heterozygosity for Hb Peterborough and Hb Lepore-Boston-Washington (Hb LBW) [delta 87, beta 116; NG_000007.3: g.63632_71046del] in a middle-aged gentleman with a history of chronic microcytic anemia and splenomegaly, presenting with severe drug-induced hemolysis, which was managed conservatively. The clinical history and presentation reflect the dual pathology due to the presence of two variant Hbs and their associated phenotypes. In this article, we discuss the phenotype resulting from the interaction of Hb Peterborough and Hb LBW and emphasize the importance of molecular testing in the diagnosis of rare Hb variants.